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Primary hypersomnia, a rare clinical syndrome, was diagnosed in a 14-year-old boy. The 
syndrome showed partial response to high dose fluoxetine therapy (120 mg/day) which recruited 
insomnia, an adverse effect of the drug, for therapeutic purposes. Response was enhanced with 
intermittent methylphenidate in association with a lower dose of fluoxetine. A possible pharmacokinetic 
interaction developed, comprising fluoxetine-induced augmentation of methylphenidate activity; such 
an interaction has not been previously reported. 
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Primary hypersomnia (DSM-IV; American 
Psychiatric Association, 1994) is a rare clinical 
syndrome, and little information is available 
about its incidence, prevalence and 
management. This report illustrates a case of 
primary hypersomnia and discusses its response 
to an experimental (fluoxetine) as well as a 
conventional (methylphenidate) treatment. A 
possible pharmacokinetic interaction between 
the two treatments is also considered. 
CASE REPORT 
VM, a 48-kg, 14 year old schoolboy, was 
brought by his parents with a history of excessive 
daytime drowsiness followed by periods of sleep. 
The complaints had been present all through his 
life since early childhood, and interfered 
significantly with daily activities; for example, he 
would fall asleep during class for periods of 15 
mins to an hour at a time, several times a day. 
Or, he would fall asleep while being transported 
to and from school. Or, he would doze during 
social visits. As a result, his studies suffered, 
and he was much teased by his friends. 
The episodes of sleep were always 
preceded by progressively increasing drowsiness 
and were never sudden in onset. The occurrence 
of drowsiness was directly related to the degree 
of environmental stimulation; for example, he 
remained alert during maths or science classes, 
or while working at a computer, but would doze 
during history lectures or when his mind was not 
actively engaged in a task. These episodes of 
sleep varied in number and duration depending 
on the challenges during the day. The sleep 
episodes were rarely refreshing. It was not 
possible to increase alertness during one part of 
day (e.g. during the evening) by restructuring 
his sleep habits or by enforcing naps (e.g. during 
the afternoon). The duration and quality of 
nighttime sleep was normal : he would sjeep 
around 10 P.M. and awake around 6 A.M. 
There were no symptoms suggestive of 
hypnagogic or hypnopompic hallucinations; 
sleep paralysis, cataplexy, breathing 
disturbances associated with sleep or any other 
symptom associated with sleep. There was no 
symptom to suggest the existence of significant 
current or previous psychiatric or medical 
morbidity. There was no history of drug use, nor 
a family history of a similar disorder. Physical 
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examination was unremarkable. Repeated EEGs 
revealed consistently reduced sleep latency but 
no sleep onset REM periods; no other 
abnormality was present. The clinical picture 
completely met DSM-IV criteria for Primary 
Hypersomnia (APA, 1994). 
After discussion with his parents, 
fluoxetine was begun as an experimental 
treatment because fluoxetine is known to 
produce dose-dependent decrease in sleep. For 
VM's disorder, therefore, an adverse effect of 
fluoxetine would be recruited as a therapeutic 
effect. Treatment commenced at 20 mg/day and 
was gradually stepped up at 3-4 week intervals. 
There was progressive decrease in daytime 
drowsiness with each increase in dose. At the 
maximum recommended dose of 80 mg/day, 
however, parents and VM rated the improvement 
at only 40-50%. This dose was maintained for 6 
months and the clinical gains continued. 
Subsequently, VM's mother independently 
increased the dose by 20 mg and then by another 
20 mg/day. Thus, VM was receiving 120 mg/day, 
which is 50% above the maximum 
recommended dose. When VM reported for his 
quarterly follow-up, he reported 80-90% 
improvement. There was little or no drowsiness 
in the morning; drowsiness and sleep spells 
during the afternoon occured only during ' boring' 
classes; and, except for a nap during his bus 
ride home, he was alert during the evening. 
However, his drowsiness and desire for sleep 
became strong by 8-9 p.m., and he would retire 
after a bath and meal to rise at around 5 a.m. 
the next day. 
VM continued fluoxetine in the dose of 120 
mg/day for 6 months with no untoward effects. 
There were no symptoms such as 
gastrointestinal distress, headaches, 
restlessness or anxiety, nor was there 
disturbance in sexual functioning. As time 
passed, however, clinical gains with fluoxetine 
showed a mild decrease. In view of continued 
problems associated with examinations (during 
which he would fall asleep), psychostimulant 
therapy with methylphenidate was 
recommended. The dose of fluoxetine was 
stepped down to 60 mg/day because of 
uncertainty of its possible interaction at high 
doses with the psychostimulant. 
At present, VM is still mildly to moderately 
impaired by his symptoms. He uses 
menthylphenidate intermittently, in a dose of 5 
mg before important occasions such as 
examinations. At this dose, he is able to complete 
his examination satisfactorily; at the higher dose 
of 10 mg, he experiences profuse sweating and 
tremors. With this treatment, VM has for the first 
time in his life passed (with credit !) in his 
exminations. 
DISCUSSION 
Primary hypersomnia is a DSM-IV term; 
a more usual term in sleep research is Idiopathic 
Central Nervous System Hypersomnia 
(Guilleminault,1994a). This syndrome was 
earlier known as essential narcolepsy, 
independent narcolepsy, NREM sleep 
narcolepsy, functional hypersomnia and 
harmonious hypersomnia. Primary hypersomnia 
differes from narcolepsy in several regards, as 
is evident from the divergent DSM-IV 
descriptions of the two disorders (APA, 1994). 
The symptoms of primary hypersomnia 
more commonly develop during adolescence or 
adult life and may be intermittent; this case is 
unusal in that the symptoms appeared during 
early childhood and were continuous in course. 
The syndrome is extremely rare and there are 
therefore no published data on its incidence or 
prevalence in the population; a clinician may not 
come across a case during a lifetime of practice. 
Behavioural approaches to treatment and sleep 
hygiene measures have little positive impact on 
the syndrome. Medications such as tricyclic 
antidepressant drugs, monoamine oxidase 
inhibitors, clonidine, L-dopa, bromocriptine, 
amantadine, methysergide and 5-hydroxy-
tryptbphan are experimental treatments which 
usually do not work well. The only medications 
that offer at least partial and intermittent relief 
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are psychostimulants such as pemoline, 
methylphenidate, mazindol, phenmetrazine 
hydrochloride and dextroamphetamine 
(Guilleminault, 1994a). Modafinil, a drug recently 
approved of for the treatment of narcolepsy, may 
also be effective. 
Psychostimulant therapy is associated 
with several disadvantages. In addition to the 
actual adverse effects of the drugs, these 
disadvantages include the development of 
tolerance to the beneficial effects and the 
occurrence of withdrawal symptoms when the 
dose is lowered or the drug is discontinued. 
Therefore, therapy for VM was initiated with 
fluoxetine rather than a psychostimulant with the 
hope that insomnia as an adverse effect of the 
drug would benefit the patient. Fluoxetine has 
been used with modest success in the narcolepsy 
syndrome (Guilleminault, 1994b); however, a 
MEDLINE search revealed no reports of its use 
in primary hypersomnia. Happily for VM, positive 
results were obtained with initiation of therapy. 
These benefits, as might have been expected 
were dose dependent. 
VM showed the best response to a dose 
of 120 mg/day. The maximum recommended 
dose of fluoxetine is 80 mg/day not because 
higher doses lead to morbid risk, but because at 
higher doses the likelihood of additional clinical 
gain is small and the risk for additional adverse 
effects is high; in fact, there are reports of 
patients tolerating overdoses of fluoxetine 
amounting to 1-3 gm (Barbey & Roose,1998). 
For this reason, in exceptional cases fluoxetine 
and related drugs have been used in doses that 
are higher than recommended (Byerly et al., 
1996; Agarwal, 1998; Andrade,1999). 
Treatment gains with fluoxetine showed 
slight decrease with the passage of months and 
drowsiness continued to be present during 
examinations and other periods of low 
stimulation. As a result, psychostimulant therapy 
became inevitable. The dose of fluoxetine was 
lowered to accomodate the initiation of 
methylphenidate therapy because of the 
uncertainty of the nature of the 
pharmacodynamic interaction between very high 
dose fluoxetine and methylphenidate. 
The response to methylphenidate was 
good; while doses of 10-40 mg/day have been 
used for patients with narcolepsy (Guilleminault, 
1994b) and clozapine-associated hypersomnia 
(Miller, 1996), VM appeared to do well with just 5 
mg/day. The efficacy of this low dose may have 
been because intermittent administration 
precludes the development of tolerance. 
However, it is also conceivable that the effective 
dose that VM received was higher through a 
pharmacokinetic interaction: fluoxetine is known 
to produce dose-dependent inhibition of the 
metabolism of several psychotropic agents and 
(particularly in high doses) it may hence retard 
the metabolism of menthylphenidate as well. 
This hypothesis is supported by evidence which 
suggests that methylphenidate, like fluoxetine, 
inhibits the metabolism of tricyclic and other 
agents (Reynolds, 1993), suggesting that the 
drug is itself metabolized by the same 
cytochrome P-450 subgroup. This hypothesis is 
also supported by the occurrence of profuse 
sweating and tremors when VM used a higher 
dose (10 mg) of methylphenidate; such 
symptoms are due to methylphenidate-induced 
overstimulation of the central nervous system, 
but do not usually occur with doses as low as 10 
mg/day. While methylphenidate augmentation 
of selective serotonin reuptake inhibitor therapy 
has been described in patients with depression 
(Stoll et al.,1996), a MEDLINE search identified 
no literature on the pharmacokinetic effects of 
fluoxetine on methylphenidate; this, therefore, 
may be the first report. 
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